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Faulty Initiation of Proteoglycan Synthesis
Causes Cardiac and Joint Defects
Sevjidmaa Baasanjav,1,2,14 Lihadh Al-Gazali,3,14 Taishi Hashiguchi,4,14 Shuji Mizumoto,4 Bjoern Fischer,1
Denise Horn,1 Dominik Seelow,1 Bassam R. Ali,5 Samir A.A. Aziz,6 Ruth Langer,7 Ahmed A.H. Saleh,6
Christian Becker,8 Gudrun Nu¨rnberg,8 Vincent Cantagrel,9 Joseph G. Gleeson,9 Delphine Gomez,10
Jean-Baptiste Michel,10 Sigmar Stricker,11 Tom H. Lindner,2 Peter Nu¨rnberg,8 Kazuyuki Sugahara,4
Stefan Mundlos,1,11,* and Katrin Hoffmann1,11,12,13,*
Proteoglycans are a major component of extracellular matrix and contribute to normal embryonic and postnatal development by
ensuring tissue stability and signaling functions. We studied five patients with recessive joint dislocations and congenital heart defects,
including bicuspid aortic valve (BAV) and aortic root dilatation. We identified linkage to chromosome 11 and detected a mutation
(c.830G>A, p.Arg277Gln) in B3GAT3, the gene coding for glucuronosyltransferase-I (GlcAT-I). The enzyme catalyzes an initial step in
the synthesis of glycosaminoglycan side chains of proteoglycans. Patients’ cells as well as recombinant mutant protein showed reduced
glucuronyltransferase activity. Patient fibroblasts demonstrated decreased levels of dermatan sulfate, chondroitin sulfate, and heparan
sulfate proteoglycans, indicating that the defect in linker synthesis affected all three lines of O-glycanated proteoglycans. Further studies
demonstrated that GlcAT-I resides in the cis and cis-medial Golgi apparatus and is expressed in the affected tissues, i.e., heart, aorta, and
bone. The study shows that reducedGlcAT-I activity impairs skeletal as well as heart development and results in variable combinations of
heart malformations, including mitral valve prolapse, ventricular septal defect, and bicuspid aortic valve. The described family consti-
tutes a syndrome characterized by heart defects and joint dislocations resulting from altered initiation of proteoglycan synthesis (Larsen-
like syndrome, B3GAT3 type).Introduction
Proteoglycans are a major component of connective tissue.
They influence the mechanical properties and contribute
to regulatory functions including cell proliferation, differ-
entiation, and development.1–9 The mechanical effect of
glycosaminoglycans (GAG) is well understood. Their
charge contributes to hydrophilic properties, and the accu-
mulating water ensures an appropriate elastic tissue tonus.
In this way, small proteoglycans such as biglycan and de-
corin help to form and modify collagen fibers in size and
organization. Important functions for proteoglycans have
been demonstrated for a number of organs including the
cardiovascular system. For example, the growth of new
blood vessels from pre-existing vasculature is influenced
by proteoglycans through modulating the bioactivity of
key angiogenic factors such as vascular endothelial growth
factor (VEGF(165)) via affecting VEGF’s diffusion, half-life,
and interactionwith its tyrosine kinase receptors.10,11 Like-
wise, the differentiation of cardiomyocytes depends on1Institute of Medical Genetics, Charite´ University Medicine, Augustenburge
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Thechanges in proteoglycan and hyaluronan concentration
during differentiation, thereby governing the differentia-
tion of precursor cells to mature functional cells.12 The
importance of these molecules is exemplified bymutations
in human disorders such as Simpson-Golabi-Behmel syn-
drome (MIM 312870), a condition with overgrowth, coarse
facies, and a high incidence of congenital heart defects.13,14
In this case mutations in glypican 3 (GPC3 [MIM 300037]),
the gene encoding a heparan sulfate proteoglycan that
binds to the exocytoplasmic surface of the plasma mem-
brane through a covalent glycosylphosphatidylinositol
(GPI) linkage, have been described. GPC3 is known to
modify the WNT, hedgehog, fibroblast growth factor, and
bone morphogenetic protein (BMP) signaling pathways.14
Proteoglycans consist of a core protein and glycosamino-
glycan side chains. The glycosaminoglycans are attached
to serine residues of the core protein via a tetrasaccharide
linkage region.5,15–17 This essential linker region always con-
tains four saccharides (13 xylose [Xyl], 23 galactose [Gal],
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Table 1. Clinical Features of the Children in This Report
Patient IV.2 Patient IV.3 Patient IV.4 Patient IV.5 Patient IV.7
Congenital Heart Defects
Bicuspid aortic valve - þ þ þ -
Aortic root dilatation - þ þ þ -
Mitral valve prolapse þ - þ þ þ
Atrial septal defect (ASD)/patent foramen
ovale (PFO)
PFO - ASD (surgically
closed)
PFO PFO
VSD - þ - - þ
Cranio-facial appearance
Brachycephaly þ þ þ þ þ
Large prominent eyes þ þ þ þ þ
Downslant palpebral fissures þ þ þ - -
Depressed nasal bridge - þ þ þ þ
Small mouth þ - - þ þ
Low set ears þ - þ - -
Small/dysmorphic ears þ þ þ - -
Micrognathia/microretrognathia þ - þ þ þ
Short/webbed neck þ þ þ þ þ
Skeletal Abnormalities
Short stature <P3a <P3 <P3 P3 P3
Dislocated joints elbow elbow shoulder, elbow,
prox. radioulnar
elbow elbow
Joint laxity (wrist and interphalangeal) þ þ þ þ þ
Elbow joint contractures þ þ þ þ þ
Broad ends of fingers and toes þ þ þ þ þ
Foot deformity (talipes varus, metatarsus varus,
and flat feet)
þ þ þ þ þ
All patients had heart and/or aortic disease as well as distinct skeletal abnormalities, including short stature and multiple joint dislocations together with variable
degree of facial dysmorphic features.
a P percentile.that are composed of repeating disaccharide units con-
sisting of an amino sugar (N-acetylglucosamine [GlcNAc]
or N-acetylgalactosamine [GalNAc]) and an uronic acid
(GlcA or iduronic acid [IdoA]). The composition of the
GAG chain defines the nature of the proteoglycan. Addi-
tional disaccharide repeat units of N-acetylglucosamine
and glucuronic acid [GlcNAc-GlcA]n produce heparans,
whereas repeats of N-acetylgalactosamine and glucuronic
acid [GalNAc-GlcA]n produce chondroitins. Modifications
such as sulfation and epimerization further increase the
structural and functional diversity of proteoglycans (see
Figure S1 available online). The synthesis of the proteo-
glycan linker region is a complex specialized process that
involves several enzymatic steps (see Figure S1 for details).
Here we describe a family with a distinct recessive
phenotype, consisting of small stature, joint dislocations,
and congenital heart defects including bicuspid aortic
valve and mitral valve prolapse. We identified mutations16 The American Journal of Human Genetics 89, 15–27, July 15, 2011in B3GAT3 (MIM 606374; ENA database AAH71961), the
gene encoding glucuronyltransferase-I (GlcAT-I) that adds
the last component of the linker region. The mutation
causes a drastic reduction of GlcAT-I activity and results
in the production of immature dermatan sulfate (DS)
proteoglycans as well as in a reduced number of chon-
droitin sulfate (CS) and heparan sulfate (HS) chains. We
describe a syndrome caused by impaired proteoglycan
maturation, providing evidence that normal side chain
synthesis is essential for the development of the heart, in
particular its valves, and the skeleton. We suggest naming
it Larsen-like syndrome, B3GAT3 type.
Material and Methods
Patients
We studied a consanguineous family with five affected children
(Table 1, Figures 1 and 2, Figure S2). All members of the family
Figure 1. Mutations in B3GAT3 Are Associated with a Specific
Phenotype
(A) Facies appeared flattened with large eyes, hypertelorism, long
and downslanting palpebral fissures, depressed nasal bridges,
and micrognathia. Note dislocation of elbow, broad fingers and
toes, and foot deformity.
(B) Radiographs show dislocation of shoulder, elbow, and prox-
imal radio-ulnar joints. Mild shortening of metacarpal bone I,
pseudoepiphysis at the second metacarpal bone, dissociation
and retardation of the bone age, and mild irregularities at several
metaphyses are shown.
(C) Echochardiography showing aortic dilation and bicuspid
aortic valve.
Numbers in left lower corner indicate the patient’s ID correspond-
ing to the pedigree and Table 1.
Thewere clinically assessed and individual organ systems studied to
ascertain the full phenotype. The study has been approved by
the Charite´ University medicine, United Arab Emirates University,
and Hokkaido University ethics committees. The procedures
followed were in accordance with the ethical standards of the
responsible committees on human experimentation (institutional
and national). Written, informed consent was obtained from all
participants or their legal guardians.
Genomic and Molecular Analysis
Genotyping was performed with the 10 k Affymetrix SNP chip.
The data were analyzed with ALLEGRO v1.2c, GENEHUNTER
v2.1r5 under the graphical user-interface easyLINKAGE
v5.08.18,19 A recessive model with complete penetrance, disease
allele frequency of 0.001, and equally distributed marker alleles
was assumed. Fine mapping with microsatellites was done as
previously described.20 We included all available family members
and reconstructed haplotypes by GENEHUNTER and manually.
We sequenced functional candidate genes within the linkage
interval by standard sequencing procedures. Functional candi-
dates were selected based on their expression potential function
and/or previously reported skeletal and cardiac phenotypes in
human or animal models, respectively, in the gene itself or associ-
ated pathway genes and interaction partners. Primer sequences of
used microsatellite markers and sequenced genes are available
upon request. The mutation was tested in controls (147 popula-
tion-matched controls and 425 blood donors of European descent)
and for correct segregation within the patient’s family.
All coding sequences and flanking intron regions of B3GAT3
(GlcAT-I, NM_012200.2, GI:12408653; NP_036332.2) were ampli-
fied and sequenced by standard protocols. Primer sequences are
provided in Table S1.
Quantitative PCR
B3GAT3 mRNA levels were studied in different tissues and cell
lines by quatitative PCR (qPCR). After cell lysis with Trizol and
standard phenol/chloroform RNA extraction, total cDNA was
transcribed by RevertAid H Minus First Strand cDNA Synthesis
Kit (Fermentas, Burlington, Ontario, Canada). For qPCR on ABI
Prism 7500 (Applied Biosystems, Foster City, CA), we mixed
cDNA, SYBR Green (Invitrogen, Carlsbad, Ca), and primers
(primer sequences in Table S1). We analyzed qPCR data with the
ABI Prism SDS Software package (DDCt method; normalization
against GAPDH).
To determine the expression levels of decorin mRNA, total RNA
was extracted from fibroblasts of each subject and cDNAs were
synthesized with reverse transcriptase by standard protocols. The
quantitative real-time RT-PCR was performed by Mx3005P (Strata-
gene, La Jolla, CA) with decorin-specific primer pairs (primer
sequences in Table S1).
Molecular Modeling
The model used was the X-ray structure of the human GlcAT-I
bound to UDP-GlcA. The Protein Data Bank code for this model
is 1KWS and is available at the RCSC protein data bank. The result
of the modeling was rendered with PyMol.
Glucuronyltransferase Activities of WT and Mutant
GlcAT-I
UDP-[14C]GlcA (180.3 mCi/mmol) was purchased from Perkin-
Elmer Life and Analytical Sciences (Boston, MA). A humanAmerican Journal of Human Genetics 89, 15–27, July 15, 2011 17
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Residue R277
Homo sapiens RPFPVDMAGFAVALPLLLDKPNAQFDSTAP R GHLESSLLSHLVDPKDLEPRAANCTRVLVWHT
Chi
B
mpanzee RPFPVGMAGFAVALPLLLAKPNAQFDSTAP R SHLESSLLSHLVDPKDLEPWAANCTRILVWHT 
Macague RPFPVDMAGFAVALPLLLAKPNAQFDSTAP R GHLESSLLSHLVDPKDLEPRAANCTRVLVWHT 
Cow RPFPVDMAGFAIALSLLLAKPNARFDATAP R GHLESSLLSHLVDPKDLEPRAANCTRVLVWHT 
Dog RPFPVDMAGFAVALSLLLAKPNAQFDATAP R GHLESSLLSHLVDPKDLEPRAANCTRVLVWHT 
Mouse RPFPVDMAGFAVALPLLLDKPNAQFDSTAP R GHLESSLLSHLVDPKDLEPRAANCTQVLVWHT 
Rat RPFPLDMAGFAVSLPLLLAKPNAQFDATAP R GHLESSLLSHLVDPKDLEPRAANCTQVLVWHT 
Xenopus tropicalis RPFPIDMAGFAVSLSLLLSHPEARFDPNAE R GFLESSLLGQLVSIGDLEPRADNCTKVWVWHT 
Ciona savignyi RPFPIDMAGFAVNLKLLFKYSEAEYSNDAP R GYLESHFLTGLKLKRHDMEAKADNCSKVLVWHT 
Ciona intestinalis RPFPIDMAGFAVNLKLLFKYSEAEYSNDAP R GYLESHFLTGLKLKRHDMEAKADNCSKVLVWHT 
Danio rerio RPFPIDMAGFAVSLRLVLTNKEALFDGDAQ M GFLESSFLQHLVTMDDLEPKADLCTKVLVWHT 
Takifugu (Fugu) RPFPMDMAGFAVSLKLVLANPDACFDGEAP M GFLESSFLKGLVTMDELEPKADNCSKVLVWHT 
Caenorhabditis elegans RPFPIDMAAFAVNISLVLSNANALFSFDVP R GYQESTFLENLGIHRYNMEPLAEMCTKVYVWHT 
Anopheles gambiae RPFPLDMAGFAISSDLLLENPQAQFSYEVE R GYQESEILRHLTIVHDMQPLANRCKDVLVWHT 
WT GlcAT-I R277Q GlcAT-I
C
R277
Q277 
UDP-GLUCURONIC ACID 
Figure 2. Molecular Analysis
(A) Pedigree of the family. All affected
family members are homozygous for the
mutation c.830G>A in exon 4 of the
B3GAT3 gene.
(B) Residue p.Arg277 (p.R277) is evolu-
tionary conserved.
(C) B3GAT3 encodes the glucuronyltrans-
ferase GlcAT-I that functions as a dimer
(light green and light brown).32,45 Residue
p.Arg277 (p.R277, blue) is involved in
substrate interaction and is critical for
binding the substrate GlcA. Note that the
side chain of p.Arg277 (p.R277) is close
to the carboxyl group at the C-5 position
of GlcA but is further away in the mutant
p.Gln277 (p.Q277). (Modeling used Pro-
tein Data Bank file lKWS for the crystal
structure of GlcAT-I interacting with
the substrate UDP-glucuronic acid [UDP-
GlcA].)GlcAT-I/pOTB7 vector (IMAGE Consortium cDNA clone, ID
number 4299539) was purchased from Open Biosystems Inc
(Huntsville, AL). Anti-FLAG M2 affinity resin, anti-FLAG Mono-
clonal antibody, Galb1-3Galb1-O-methyl, and p3XFLAG-CMV8
vector were purchased from Sigma (Saint Louis, MO). An ECL
advance western blotting detection kit and Hybond-P membranes
were purchased from GE Healthcare (Buckinghamshire, UK).
FuGENE 6 transfection reagent was purchased from Roche Diag-
nostics (Basel, Switzerland). Restriction enzymes were purchased
from New England Biolabs (Hitchin, UK). KOD-Plus DNA poly-
merase was purchased from Toyobo (Tokyo, Japan). AG 1-X8 resin
(100–200 mesh) was purchased from Bio-Rad (Hercules, CA).
The expression vector of human GlcAT-I was constructed as
described previously.21,22 In brief, a truncated form of GlcAT-I
(wild-type), lacking the first NH2-terminal 43 amino acids of the
GlcAT-I, was amplified by PCR with a 50 primer containing an
in-frame EcoRI site (50-GCGAATTCACTACGGCAGAAGGAT-30)
and a 30 primer containing a SalI site located 71 bp downstream
of the stop codon (50-GCGTCGACGAAAACCACATCCT-30) and
hGlcAT-I/pOBT7 as a template. We carried out two rounds of18 The American Journal of Human Genetics 89, 15–27, July 15, 2011PCR for the construction of the amino
acid-substituted mutant of GlcAT-I
(p.Arg277Gln). The first PCR was per-
formed with a 50 primer containing an
in-frame EcoRI site (50-GCGAATTCACT
ACGGCAGAAGGAT-30) and a 30 internal
mutagenic oligonucleotide primer (50-CA
GGTGGCCCTGGGGAGCGGTGGA-30), 50
internalmutagenic oligonucleotide primer
(50-TCCACCGCTCCCCAGGGCCACCTG-
30), and 30 primer containing a SalI site (50-
GCGTCGACGAAAACCACATCCT-30) and
hGlcAT-I/pOBT7 as a template (underlin-
ing indicates modified nucleotides). The
second PCR was performed with a 50
primer containing an EcoRI site (50-
GCGAATTCACTACGGCAGAAGGAT-30),
30 primer containing a SalI site located
71 bp downstream of the stop codon (50-
GCGTCGACGAAAACCACATCCT-30), and
the first PCR products as a template. PCRwas carried out with KOD-Plus DNA polymerase by 30 cycles of
94C for 30 s, 55C for 42 s, and 68C for 60 s. The amplified frag-
ments were digested with EcoRI and SalI and inserted into
p3XFLAG-CMV8.
The expression plasmid (6.7 mg) was transfected into COS-7
cells (Japan Health Sciences Foundation, Tokyo, Japan) on
a 100 mm dish with FuGENE 6 according to the instructions
provided by the manufacturer. Three days after transfection,
0.25 ml each of the culture medium was collected and incubated
with 10 ml of anti-FLAG M2 affinity resin overnight at 4C. The
beads were recovered by centrifugation and washed with 1 ml
of 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 0.05%
Tween 20, and then resuspended in the assay buffer for enzyme
activity.
The culture medium (0.2 ml) was incubated with 10 ml of anti-
FLAGM2 affinity resin overnight at 4C. The beads were recovered
by centrifugation, washed with TBST, and then analyzed on
a 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel, trans-
ferred to a polyvinlidene difluoride (PVDF) membrane, and incu-
bated for 1 hr with FLAG antibody. The bound antibody was
detected with anti-mouse IgG conjugated with horseradish
peroxidase.
Enzyme Assay of the Recombinant WT and Mutant GlcAT-I
The glucuronyltransferase assay mixture contained 10 ml of the
resuspended anti-FLAG affinity resins/50 mM 2-(N-morpholino)
ethanesulfonic acid-NaOH (pH 6.5)/171 mM ATP/10 mM MnCl2/
14.3 mM UDP-[14C]GlcA (1.77 3 105 dpm)/60 nmol Galb1-
3Galb1-O-methyl as acceptor substrate in a total volume of
30 ml. The reaction mixture was incubated at 37C for 1 hr.
The 14C-labeled products were isolated by applying the reaction
mixture onto a tiny tip column packed with AG 1-X8 resin
(a PO4
2 form, 100–200 mesh) to remove excess UDP-[14C]
GlcA.23 The isolated products were quantified in a liquid scin-
tillation counter (LS6500, Beckman coulter).
Comparison of the GlcAT-I Activities of Fibroblast Homogenates from
Patients and Age-Matched Controls
The following fibroblasts were used for the assay. Age-matched
controls for patient A820 (male, 11 years old) were GM03348E
(male, 10 years old) and AG16409 (male, 11 years old). Age-
matched controls for patient A821 (male, 17 years old) were
GM07492A (male, 17 years old) and GM07753 (male, 17 years
old). The homogenates of the fibroblasts were assayed with
Galb1-3Galb1-O-methyl as an acceptor (220 nmol) and UDP-[14
C]GlcA as a donor substrate, and then incubated for 4 hr at 30C.Immunofluorescence
For immunofluorescence analysis, the cells were washed three
times in phosphate-buffered saline (PBS), fixed in 4% paraformal-
dehyde for 10 min at 4C, and permeabilized in 3% BSA in 13 PBS
with 0.4% Triton X-100 for 10 min at 4C. GlcAT-I protein was
detected by a mouse anti-GlcAT-I polyclonal antibody (Abnova,
Taipei, Taiwan: H00026229-B01P). For testing the colocalization
analysis with Golgi proteins, we used sheep anti-GM130 (kind
gift by Francis A. Barr), rabbit anti-Giantin (Covance, Princeton,
NJ), and sheep anti-TGN46 (Serotec, Oxford, UK). As secondary
antibodies we applied anti-mouse IgG Alexa Fluor 555 (Invitrogen,
Molecular Probes) and an anti-sheep/rabbit IgG Alexa Fluor 488
(Invitrogen, Molecular Probes) conjugates. We stained DNA by
DAPI and mounted cells in Fluoromount (Scientific Services,
Cornwall, UK). Images were collected with an LSM 510 meta
(Carl Zeiss, Go¨ttingen, Germany) with a x63 Plan Apochromat
oil immersion objective.Immunoblotting of Aortic Media Extracts
Normal walls of the ascending aorta and aortic arch were obtained
in healthy subjects at the time of organ collection for heart/lung
transplantation with the authorization from the French Biomedi-
cine Agency. Protein extractions were performed directly from
frozen aortic media (after the separation from intima and adven-
titia) and stored at80C. Themedia preparations were pulverized
in liquid nitrogen, using a freezer mill (model 6750 SPEX Sample-
Prep, Metuchen, NJ), and subsequently homogenized in a hypo-
tonic lysis buffer (50 mM Tris [pH 8], 150 mM NaCl, 1% Triton
X-100, 1% sodium deoxycholate, 5 mM EDTA) containing a cock-
tail of protease and serine/threonine and tyrosine phosphatase
inhibitors (Sigma). The protein concentration from each sample
was determined and extracts were separated by 10% SDS-poly-
acrylamide gel electrophoresis. Proteins were transferred to
a PVDF membrane, blocked with 5% BSA-TBS-T (Tris-buffered
saline [pH 7.4]-0.1% Tween 20) for 1 hr. Membranes were then
incubated overnight (4C) with primary antibodies: polyclonalTheB3GAT3 (1 mg/ml, Abnova), monoclonal B3GAT3 (1 mg/mL,
Abnova), or GAPDH (1.6 mg/ml, Biovalley, Freiburg, Germany).
Membranes were then washed with TBS-T and incubated with
anti-mouse IgG (Jackson Laboratories, Bar Harbor, ME) for 1 hr.
The signal was detected with a chemiluminescence kit (ECL Plus
kit; Amersham).
Analyses of Dermatan Sulfate, Chondroitin Sulfate,
and Heparan Sulfate Proteoglycans in Patient and
Control Fibroblasts
The serum-free conditioned medium of the cultured fibroblasts of
control subjects and patients was collected and concentrated
with Amicon Ultra-4 (Ultracel-30k, Millipore, Billerica, MA). An
aliquot of the medium (5 mg as total protein) was digested with
a highly purified (protease-free) chondroitinase (CSase) ABC (EC
4.2.2.20, Seikagaku Corp., Tokyo, Japan), and each digest was sub-
jected to SDS-polyacrylamide gel electrophoresis. Western blotting
was carried out with an anti-human decorin antibody (clone
115402, R&D Systems, Minneapolis, MN) and an ECL advance
detection kit (GE healthcare).
For determination of the number of CS and HS chains, cultured
fibroblasts from patients and control subjects (age and sex
matched) were collected and washed with PBS. The cells were
treated with CSase or a mixture of heparinases (HSases) -I
(EC 4.2.2.7) and -III (EC 4.2.2.8) (IBEX Technologies, Montreal,
Canada) at 37C for 1 hr. After washing with PBS, CSase- or
HSase-treated cells were individually incubated with the primary
antibodies, anti-CS-stub (2B6) and anti-HS-stub (3G10) (Seikagaku
Corp.), and subsequently the cells were incubated with the Alexa
Fluor 488-labeled anti-mouse IgM secondary antibody (Molecular
Probes, Eugene, OR). Incubation of the fibroblasts with the sec-
ondary antibody alone was also performed as a negative control
experiment. Alexa Fluor 488-bound cells were analyzed by
immunofluorescence flow cytometry in a BD FACSCanto (BD
Biosciences, San Jose, CA).Results
Patients’ Phenotype Defines a Syndrome
Characterized by Joint Dislocations and Congenital
Heart Defects Including Bicuspid Aortic Valve
The parents were first cousins with five affected and two
unaffected children (Figures 1 and 2, Figure S2, Table 1).
All five patients had congenital heart defects in variable
combinations (Figure 1C, Table 1). Bicuspid aortic valve
with dilatation of the aortic root was present in three,
mitral valve prolapse in four, patent foramen ovale in
three, and ventricular septal defect in two of the patients.
All affected children had short stature (height < 3%) and
presented variable craniofacial dysmorphic features which
included brachycephaly, thick eyebrows, large eyes with
downslanting palpebral fissures, depressed nasal bridge,
narrow mouth, and micrognathia or microretrognathia.
The ears in some of them were small, low set with promi-
nent antitragus, and slight uplift of the lobe. The neck
was short (webbed in IV.2) with low posterior hair line.
There was mild chest asymmetry.
In addition, all affected individuals had congenital
dislocations and contractures of the elbow joint as wellAmerican Journal of Human Genetics 89, 15–27, July 15, 2011 19
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Figure 3. Expression and Activity of GlcAT-I
(A) GlcAT-I activity in fibroblasts is markedly reduced in patients compared to age-matched controls. The homogenates of the fibroblasts
were assayed with Galb1-3Galb1-O-methyl as an acceptor (220 nmol) and UDP-[14C]GlcA as a donor substrate, and then incubated for
4 hr at 30C. The results are from duplicate experiments. Unit is pmol/mg protein/hr.
(B) Reduced amount of mutant GlcAT-I and loss of Golgi localization in patient’s fibroblasts. By comparison, GlcAT-I (red) colocalizes
with the cis and cis-medial Golgi marker GIANTIN (green) in wild-type fibroblasts.
(C and D) Glucuronyltransferase activities of the human recombinant GlcAT-I (WT and p.Arg277Gln) showed similar amounts of
proteins (C) but reduced activity by mutation p.Arg277Gln (D).
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as talipes equinovarus and/or metatarsus varus. Joint
dislocations were also observed in the shoulders. Joint
laxity was present in the wrists and interphalangeal
joints. The finger tips and the hallux on both sides ap-
peared wide. Radiographs showed dislocations of the
shoulder, elbow, and proximal radial-ulnar joints (Figure 1),
a mild shortening of the first metacarpal bone, delayed
and dissociated bone age (~4 years at the chronological
age of 8 years), mild dysplasia of the hip joints, and foot
deformities. The vertebral column showed signs of osteo-
penia; several vertebrae were already flattened. The chil-
dren had a normal mental and motor development.Disease Mapping and Identification of the Disease-
Causing Mutation in B3GAT3
We performed genome-wide linkage analyses and mapped
the disease to chromosome 11q12 (multipoint LOD ¼
3.76; Figure S3A). Fine mapping narrowed the region to
an 8 cM interval (final multipoint LOD ¼ 3.89;
Figure S3B) containing 262 genes. We sequenced 30 func-
tional candidate genes within this region (Table S2). We
identified the homozygous missense mutation c.830G>A
in B3GAT3, the gene encoding the enzyme beta-1,3-glu-
curonyltransferase 3 (GlcAT-I), which resulted in the
substitution of arginine at position 277 by glutamine
(p.Arg277Gln). The mutation p.Arg277Gln segregated
with the disease in the family (Figure 2A) and was present
neither in 294 chromosomes from population-matched
controls nor in 850 chromosomes from Berlin blood
donors. Residue p.Arg277 is evolutionary highly conserved
and alters a functionally important domain involved in
substrate interaction, especially in binding the substrate
GlcA (Figures 2B and 2C).Reduced GlcAT-I Enzyme Activity in Patient Cells
The p.Arg277 residue has previously been shown to be
essential for enzymatic activity in a mutagenesis experi-
ment (p.Arg277Ala) by ensuring GlcAT-I substrate spe-
cificity.24 We therefore reasoned that the mutation
p.Arg277Gln might have a similar effect on GlcAT-I
activity. Our studies in the homogenates from patient-
derived fibroblasts demonstrated that the missense muta-
tion p.Arg277Gln results in a significant reduction of glu-
curonyltransferase activity. GlcAT-I activity in patient(C) For western blotting, the purified recombinant FLAG-GlcAT-I (W
gel electrophoresis and detected with the FLAG M2 antibody. The a
light and heavy chains of the antibody, which is derived from the a
(D) Catalytic GlcAT-I activity of the recombinant enzyme (p.Arg277G
averages and standard error of two independent experiments, whichw
ase activity obtained with the conditioned medium transfected with a
(E) The GlcAT-I antibody (Abnova) recognizes both the wild-type a
antibody binding to the wild-type. (Western blotting in Figure S5.)
(F) RNA-expression of B3gat3 in different disease relevant tissues (obt
well as from osteoblast and osteoclast cell cultures. Data were obtain
error of the mean [SEM]).
(G) Western blotting of GlcAT-I in human aorta. Western blotting
wild-type aorta.
Thefibroblasts (patients IV.2 and IV.4) was reduced to 3%–5%
of age-matched control levels (Figure 3A). Thus, mutant
cells showed a drastic reduction in GlcAT-I activity but still
showed some basal activity, indicating that the mutation
is hypomorphic.
By using immunofluorescence and colocalization with
Golgi-marker proteins, we showed that GlcAT-I is located
in the cis and cis-medial Golgi (Figure S4). In mutant cells
the protein level is dramatically reduced (Figure 3B). We
tested whether the antibody detects both the wild-type
and the mutant protein and found that the mutation did
not affect antibody binding (Figure S5), whereas mutation
c.830G>A did not significantly reduce the level of B3GAT3
mRNA (data not shown). These observations suggest that
the mutant GlcAT-I protein might have been degraded or
produced to a lesser extent as compared to the wild-type.
As previously shown, artificially introduced missense
mutations can reduce enzymatic activity and secondarily
decreased stability of the mutant, dysfunctional enzyme
by ER retention and subsequent proteasomal decay.25
To test whether the mutation p.Arg277Gln indeed
reduces GlcAT-I activity by impaired enzymatic function
and not by primary reduced protein level, we transfected
cells with the human GlcAT-I wild-type and the mutated
(p.Arg277Gln) vector. We found a marked reduction of
GlcAT-I activity in the mutant despite similar amounts of
the wild-type and mutant proteins (Figures 3C–3E), sug-
gesting that the reduced enzymatic activity of GlcAT-I
affects protein stability.Expression of GlcAT-I in Heart, Aorta, and Bone
Individuals with the c.830G>A mutation showed heart
defects, aortic root dilatation, and skeletal malformations.
Reverse-transcriptase quantitative PCR on corresponding
mouse tissues demonstrated that B3GAT3 mRNA is ex-
pressed in heart, aorta, bone, and also in osteoblasts
(Figure 3F). In addition, GlcAT-I protein was present in
human aorta (Figure 3G).GlcAT-I Mutations Are Associated with Immature DS
Proteoglycans as well as with Reduced Amounts of CS
and HS Chains in Patient Cells
We tested how the reduced enzyme activity affects the
products of proteogylcan synthesis. The overall amountT and p.Arg277Gln) was separated by 12.5% SDS-polyacrylamide
rrowhead and asterisks indicate the recombinant enzyme and the
nti-FLAG agarose resin used for purification, respectively.
ln) was reduced compared to the wild-type. Activities represent the
ere performed in duplicate.Mock indicates the glucuronyltransfer-
n empty vector as a control. Experiments were performed at 37C.
nd the mutant recombinant GlcAT-I, thus excluding preferential
ained from newborn black 6 mice [C57BL/6], postnatal day P4) as
ed from three different experiments (error bars represent standard
shows presence of GlcAT-I in medial tissue extracts from human
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Figure 4. Effect of GlcAT-I Mutations on
DS, CS, and HS Proteoglycan Synthesis
(A) DS-free decorin is detected in patient
but not in control fibroblasts, indicating
an insufficient dermatan sulfate synthesis.
Western blotting of a DS-proteoglycan,
decorin, produced by fibroblasts. The
conditioned medium derived from wild-
type fibroblasts showed a broad band of
decorin-proteoglycan around 60–120 kDa.
In contrast, the conditioned medium
derived from the patient fibroblasts re-
vealed two bands. The upper band repre-
sents decorin-proteoglycan with a DS
chain. The lower band ~50 kDa is pre-
dicted to be decorin with only the linkage
region trisaccharide (Gal-Gal-Xyl), with-
out a DS chain. These observations suggest
that the mutation p.Arg277Gln in GlcAT-I
is associated with insufficient synthesis of
dermatan sulfate proteoglycan.
Control: age-, sex-, and population-
matched (male, 11 years old, AG16409);
patient IV.4: male, 11 years old (mutation
p.Arg277Gln in GlcAT-I, A820). The arrow
indicates DS-free decorin.
(B) Experimental design for analyzing CS
and HS synthesis. The unsaturated hexur-
onic acid containing CS and HS, which
were generated by the treatment with
CSase or HSase, are recognized by the
anti-CS-stub and anti-HS-stub antibodies,
respectively.
Anti-stub CS (2B6) and anti-stub HS
(3G10) antibodies can recognize the unsat-
urated hexuronic acid-containing oligo-
saccharide that are generated by the treat-
ment with bacterial CSase and HSase,
respectively, whereas neither intact CS
nor HS can be recognized. Therefore, these
antibodies can be used as probes for inves-
tigating the relative number of CS and HS
chains on the core proteins of proteogly-
cans. It should be noted that the truncated
GAG-protein linkage trisaccharide Gal-
Gal-Xyl- expressed on core proteins in
the GlcAT-I mutant cells is not recognized
by either antibody.
(C and D) Analysis of the relative number
of CS and HS chains expressed on the cell
surface of fibroblasts by flow cytometry.
To examine the expression of CS and HS
on the cell surface, the fibroblasts from
the 11-year-old patient IV.4 and from
controls (AG16409) were treated with CSase and then with anti-stub 2B6 antibodies (C) or HSase and then with anti-stub 3G10 anti-
bodies (D), respectively. The binding of these antibodies to the epitopes on the cell surface was visualized by flow cytometry after incu-
bating with Alexa Fluor 488-conjugated secondary antibody. The gray and white histograms show the intensity of the fluorescence with
or without anti-stub antibody, respectively. Similar results were also obtained with those from the 17-year-old patient IV.2 (Figure S6B).of GAGs in fibroblasts from patients did not show an
obvious decrease compared to that of age-matched
controls (data not shown). Next we analyzed the proteo-
glycan decorin in fibroblasts from patients by western
blotting. Decorin is secreted by fibroblasts and has
a single DS chain when proteoglycan synthesis is undis-
turbed. We detected DS-free decorin in the patients’ cells
but not in control fibroblasts (Figure 4A; Figure S6), sug-
gesting that the mutation p.Arg277Gln in GlcAT-I results22 The American Journal of Human Genetics 89, 15–27, July 15, 2011in the production of the immature DS-proteoglycan de-
corin.
We examined specifically decorin proteoglycan by
western blotting by using the conditioned media from
fibroblasts of patients IV.2 and IV.4. One broad-band of de-
corin-proteglycan (around 80 kDa) was detected in control
fibroblasts. In contrast, we detected two bands in fibro-
blasts from both patients (Figure S6A, lanes 3 and 6). The
upper band was decorin proteoglycan with a DS chain as
shown in the wild-types (Figure S6A, lanes 1, 2, 4, and 5),
whereas the lower band (~50 kDa) is predicted to be DS-
free decorin with the linkage region trisaccharide stub,
Galb1-3Galb1-4Xyl, where Gal and Xyl stand for D-galac-
tose and D-xylose, respectively. Furthermore, the lower
band corresponded to the band observed for the con-
ditioned medium treated with CSase ABC (Figure S6).
Thus, the lower band in patients was most probably the
signal of DS-free decorin. These observations suggest that
the mutation of GlcAT-I (p.Arg277Gln) was responsible
for the lack of a DS chain on the core protein.
Based on the result from western blotting of decorin, the
amount of its core protein seemed to be upregulated.
Therefore, we analyzed the expression level of decorin
mRNA by quantitative RT-PCR. Interestingly, the mRNA
levels of decorin were 3- to 4-fold increased in patients
compared to control fibroblasts (Figure S7), indicating
that decorin mRNA levels might be upregulated to
compensate for the immature decorin.
Next we examined the synthesis of CS and HS chains on
the surface of fibroblasts from patients and age- and sex-
matched controls by flow cytometry with CS-stub and
HS-stub antibodies (Figures 4B–4D; Figure S6B). The 2B6
antibody, which recognizes the oligosaccharides contain-
ing the unsaturated hexuronic acid after treatment with
CSase, showed a markedly reduced binding to the epitopes
on the patient cells relative to those of the control subject
(Figure 4C), showing a bimodal distribution of the cells. To
quantify the relative amounts of the CS chains, the mean
fluorescence intensity (MFI) of the cell population stained
with 2B6 was used. The MFI value for the patient IV.4 was
6.0 (65%) as compared with 9.2 of the age-matched control
subject. The 3G10 antibody, which recognizes the oligo-
saccharides containing the unsaturated hexuronic acid
after the treatment with HSase, also showed a reduced
binding to the epitopes on the patient cells relative to
those of the control subject (Figure 4D). The MFI value
after staining with 3G10 was 21.4 (53%) for the patient
IV.4 as compared with 40.3 for the age-matched control
subject. Similar results were obtained for the fibroblasts
from patient IV.2 (Figure S6B). These differences in the
MFI values correspond to those of the numbers of the CS
and HS chains at cell surface of the control and the patient
cells. Namely, the number of the CS and HS chains was
reduced to 65% and 53% of the control, respectively. The
bimodal distribution of the cells from the 11-year-old
male patient (Figure 4C) suggests two different cell popula-
tions, one with a reduced number of GAG polysaccharides
most probably with a trisaccharide stub (Gal-Gal-Xyl), and
the other with a larger number of GAG polysaccharides.
Interestingly, the same seems to be true for the fibroblasts
from the 17-year-old normal subject (Figure S6B). A possi-
bility is the age-dependent bimodal cell population with
a smaller and a larger number of GAG polysaccharides,
which remains to be investigated.
These results suggest that the mutant GlcAT-I cannot
transfer GlcA to a significant portion of the linker regionThetrisaccharide Gal-Gal-Xyl, resulting in the partial defi-
ciency of all three lines of O-glycanated proteoglycans
(CS, HS, and DS proteoglycans).Discussion
We describe a family with recessive inheritance of heart
and/or aortic disease as well as of distinct skeletal abnor-
malities (short stature, multiple joint dislocations) and
variable cranio-facial dysmorphic features (Larsen-like
syndrome, B3GAT3 type).
There are some similarities to otopalatodigital syndrome
type II (OPD2 [MIM 304120]), particularly the downslant-
ing palpebral fissures, narrow mouth, contractures at the
elbows, and broad fingertips and hallux. However, the
radiological changes in OPD2 are different and the inheri-
tance is X-linked recessive rather than autosomal recessive.
Short stature, short webbed neck, and the facial appear-
ance of the children in this report could also suggest
Noonan syndrome. Nevertheless, the presence of joint
dislocations and the recessive pattern of inheritance in
this family made this diagnosis unlikely. Absence of the
typical radiological changes seen in Desbuquois syndrome
(DBQD [MIM 251450]) in this family ruled this diagnosis
out. We also considered the classic Larsen syndrome (LRS
[MIM 150250]) caused by dominant FLNB (MIM 603381)
mutations particularly because there are multiple joint
dislocations, broad fingertips, and hallux but the facial
appearance is different, the bone age is delayed rather
than advanced, and the inheritance is recessive in our
family. There are also many similarities of the family in
this report to the autosomal-recessive Larsen syndrome,
CHST3 type. This disorder includes a spectrum of pheno-
types ranging from Larsen syndrome, humerospinal dysos-
tosis, chondrodysplasia multiple dislocations, and spon-
dylo-epiphyseal dysplasia, Omani type.26–28 Children
present at birth with reduced length and multiple joint
dislocations. During childhood, the dislocations improve
and features of SED-OT appear. These features include
intervertebral disc degeneration, rigid kyphoscoliosis, and
trunk shortening. The bone age is also delayed. There are
usually vertebral changes on lateral X-ray of the spine.
These include superior and inferior notching reminiscent
of a partial coronal cleft.26 Involvement of the heart valves
in this disorder has also been reported. There are no verte-
bral changes on radiological examination in our family
and clinically the older children in our family (now 17,
14, and 13 years old) have no kyphoscoliosis or trunk
shortening. However, differentiation between these two
disorders is difficult in infancy and early childhood. The
combination of brachycephaly, downslanting palpebral
fissures, retrognathia, and abnormal ears with club feet,
hypermobility of the joints of the hands, shoulders, and
feet together with congenital heart disease raised the possi-
bility of musculocontractural EDS (previously known as
adducted thumb-clubfoot syndrome and EDS type VIB),American Journal of Human Genetics 89, 15–27, July 15, 2011 23
which is caused by mutations in CHST14.29–31 However,
the children in this report have normal build and skin
with no delay in wound healing and no contractures of
the fingers.
Here we describe that mutations in B3GAT3, the gene
coding for GlcAT-I, result in a condition characterized by
congenital dislocations, short stature, and heart defects
including bicuspid aortic valve. GlcAT-I functions as
a dimer of two subdomains with donor and acceptor spec-
ificity.32 The active sites resides in a cleft between the two
chains in which the new incoming saccharide is oriented,
chemically reduced, and eventually fused to the already es-
tablished trisaccharide linker.32,33 Ouzzine et al. used
in vitro mutagenesis to test which residues define the
substrate specificity of GlcAT-I. They identified residue
277 (mutagenesis p.Arg277Ala) as important and
concluded that the arginine at position 277 is essential
for GlcAT-I substrate specificity.24,34 Our studies in a re-
combinant cell system as well as in the homogenates
from patient-derived fibroblasts demonstrated that the
missense mutation p.Arg277Gln significantly reduces the
glucuronyltransferase activity (GlcAT-I). Nevertheless, cells
with mutant GlcAT-I had residual basal activity in the
patient fibroblasts and in vitro, indicating that the
mutated protein is still able to function.
We show that reduced GlcAT-I activity affects major
components of the extracellular matrix, resulting in imma-
ture DS proteoglycans as well as in a reduced number of CS
and HS chains in patient cells. The mutation affects the
final step in the synthesis of the tetrasaccharide linker
region, which is required for initiation of GAG side chain
synthesis of proteoglycans. Our data demonstrate that
GlcAT-I is located in the cis and cis-medial Golgi. This is
consistent with the catalytic function in glycosylation of
the Golgi apparatus and the identification of the GlcAT-I
rat ortholog in an endoplasmic reticulum (ER)/Golgi
proteomics screening perfomed in rat liver homoge-
nates.35
We found that an impairment of GlcAT-I function affects
the synthesis of CS, DS, and HS. DS-free decorin proteogly-
cans were present in the patient fibroblasts but not in
controls. These results suggest that the GlcAT-I mutation
p.Arg277Gln results in the synthesis of immature proteo-
glycans, i.e., GAG-free proteoglycans such as DS-free de-
corin. Interestingly, the synthesis of the decorin core
protein was upregulated, probably to compensate for the
dysfunctional decorin. In addition, mutant cells showed
an apparent reduction in the relative number of CS and
HS chains. This is consistent with the essential role of
GlcAT-I in proteoglycan synthesis as the last step in linker
synthesis before its division into CS, DS, and HS. Thus, any
type of the affected GAG chains (CS, DS, or HS) may
contribute to the characteristic symptoms of the patients.
Another step in linker synthesis, the addition of the
second galactose residue, is affected in progeroid type
Ehlers-Danlos syndrome (EDS progeroid form [MIM
130070]).36–38 The phenotypic overlap with the family24 The American Journal of Human Genetics 89, 15–27, July 15, 2011described here includes multiple joint dislocations, growth
delay, skeletal malformations, and hypomineralization
(osteopenia). Considerable overlap is also apparent with
defects in another downstream enzyme which is essen-
tial for CS synthesis, chondroitin 6-O-sulfotransferase-1
(C6ST1 [MIM 603799]). Mutations in the gene carbohy-
drate sulfotransferase 3 (CHST3 [MIM 603799]), coding
for C6ST1, were shown to cause autosomal-recessive spon-
dyloepiphyseal dysplasia with joint dislocations CHST3
type, a condition characterized by congenital joint disloca-
tions (especially of the knee and elbow), club foot, verte-
bral changes (platyspondyly, intervertebral disc degenera-
tion, scoliosis), short stature, arthritis, and heart defects
(MIM 245600).22,27,28 Mutations in chondroitin synthase
1 are associated with brachydactyly, mutations in the
chondroitin beta-1,4-N-acetylgalactosaminyltransferase-1
with neuropathies.39–41 A defect in the downstream
enzyme in dermatan sulfate synthesis (dermatan 4-O-sul-
fotransferase 1, D4ST1, encoded by the gene carbohydrate
sulfotransferase 14, CHST14 [MIM 608429]) results in ad-
ducted thumb-clubfoot syndrome (ATCS [MIM 601776]),
as well as a subtype of Ehlers-Danlos syndrome (EDS, mus-
culocontractural type [MIM 601776]).29,31 D4ST1 defects
lead to a reduction in DS chains. Lack of DS chains was
shown to impair the interaction with collagen to form
collagen bundles.31 Thus, proteoglycans devoid of DS
chains may explain symptoms such as skin and joint laxity
as well as tissue fragility. GlcAT-I defects also affect DS
chains and accordingly symptoms of patients with
GlcAT-I mutations overlap with these other clinical enti-
ties. However, defective linker synthesis additionally
affects CS and HS proteoglycans.
We report a disease-causing mutation resulting in
a defect terminal step of tetrasaccharide linkage region of
proteoglycans synthesis. The phenotypes we observed in
the affected individuals, namely joint dislocations,
congenital heart defects, and short stature, overlap with
symptoms seen in progeroid type EDS and in patients
with spondyloepiphyseal dysplasia with congenital joint
dislocations, CHST3 type. These findings suggest that
proteoglycan synthesis pathwaymutationsmay be respon-
sible for atypical connective tissue disorders that feature
joint dislocations, joint laxity, and congenital heart
disease.
All patients described had congenital heart disease in
various forms: mitral valve prolapse, bicuspid aortic valve
with aortic root dilatation, ventricular septal defect, and
atrial septal defect. Defects of heart valves are one of the
most common inborn malformations. Among them,
bicuspid aortic valve (BAV) is most frequent with a preva-
lence of 1%–2% in newborns.42 Bicuspid aortic valves
feature a significantly increased risk of life-threatening
late complications such as aortic root dilatation, dissection
of the aorta, and stenosis or insufficiency of the aortic
valve with subsequent heart failure. In contrast to other
congenital heart defects where already multiple genes
were found to be involved, the genetic etiology of bicuspid
aortic valve remained mostly unresolved.42,43 So far only
one gene, NOTCH1 (MIM 190198), was described for
bicuspid aortic valve.44 Thus, to the best of our knowledge,
GlcAT-I defects appear to be the second gene pathogeneti-
cally related to this frequent and clinically relevant heart
defect.
Our findings show that mutations affecting the proteo-
glycan linker region cause another subtype of connective
tissue disorders and suggest pathogenetic relevance for
a spectrum of congenital heart defects, including bicuspid
aortic valves.Supplemental Data
Supplemental Data include seven figures and two tables and can
be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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